Citations

Showing 10 of 108119 citations.

RV free wall longitudinal strain as an independent predictor of survival in wtATTR-CA patients
Tan, Tow-Shung, Grogan, Martha , Borgeson, Daniel D., Garvan, Kane C, Oğuz, Didem , Lin, Grace , Pislaru, Sorin V. , Dispenzieri, Angela

Mayo Clinic

European Heart Journal | October 18, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehab724.005 Get It

Abstract Background Wild type transthyretin cardiac amyloidosis (wtATTR-CA) is increasingly recognized as a cause of heart failure with preserved ejection fraction (HFpEF) but prognosis is often limited due to late or misdiagnosis.Longitudinal left ventricular strain and biomarkers are established as markers of disease severity, but the role of RV free wall strain, reflecting RV contractility, is less well understood. Purpose We sought to determine whether RV free wall strain might add incremental prognostic value in wtATTR-CA. Methods Consecutive patients diagnosed with wtATTR-CA with tissue confirmation at Mayo clinic between 2013 and 2015 were included. Patients with TTR gene mutations were excluded. Baseline characteristics and transthoracic echocardiography measurements were obtained from the medical records. Speckle tracking RV free wall longitudinal 2D strain and peak LA longitudinal 2D strain were measured using Tom Tec Imaging System. Survival was determined using Kaplan Meier estimates and using the cox proportional hazard ratio, univariate and multivariable analysis were performed to identify predictors of mortality in patients with wtATTR. Results The study group comprised 139 patients (mean age 74.9±8.6, 92.8% male), of which 102 had adequate image quality for RV strain, and 99 for LA strain. Amongst these, 102 (73.3%) had AF and 118 patients (84.8%) had HF. During 3.23±2.0 years of follow up, 66 patients died. Both mean RV and LA strain were impaired at baseline: RV free wall strain was −14.7±4.9, and peak atrial longitudinal strain (PALS) was 13.2±8.8%. Using ROC analysis, RV strain of −16.8% was an independent predictor of all-cause mortality. In univariate modeling, higher levels of NT-proBNP (HR: 1.1 per 1000 pg.ml; 95%, CI 1.05–1.15, p<0.001) and Troponin T (HR: 2.0 per 0.1ng/ml; 95% CI 1.49–2.61, p<0.001) were associated with increased all-cause mortality. In addition, LV GLS (HR: 1.13 per 1%; 95% CI1.04–1.24, p=0.003), RV free wall LS (HR: 2.16 per 5%; 95%, CI 1.57–3.03, p<0.0001), and PALS (HR: 0.91 per1%; 95% CI 0.85–0.96, p<0.0001) were univariate predictors of all-cause mortality. In multivariate analysis using a stepwise regression model, RV free wall longitudinal strain (HR: 1.81; 95% CI 1.29–2.62, p<0.001) and Troponin T (HR: 1.7; 95% CI 1.25–2.26, p=0.001) remained independent predictors. Kaplan-Meier survival analysis demonstrated a higher mortality rate above −16.8 RV strain cut-off (Wilcoxon <0.0001). All stages were divided into two groups by −16.8% RV strain, and survival in individual stages analyzed. Stage 1 and 2 with <−16.8 RV free wall strain value had higher mortality than ≤-16.8% RV strain (Stage 1: Wilcoxon = 0.0041 and Stage 2: Wilcoxon = 0.023). However, there was not a survival difference between two RV strain groups in stage3 (Wilcoxon = 0.34) Conclusion RV free wall strain is an independent predictor of survival in wtATTR patients and may add incremental prognostic value to NT-proBNP and Troponin. Funding Acknowledgement Type of funding sources: None. Kaplan-Meier curve of all patientsKaplan-Meier curve of stages
Supplementing Existing Societal Risk Models for Surgical Aortic Valve Replacement With Machine Learning for Improved Prediction
Kilic, Arman , Habib, Robert, Miller, James , Shahian, David M. , Dubrawski, Artur , Dubrawski, Artur W , Dearani, Joseph A.

Mayo Clinic

Journal of the American Heart Association | October 18, 2021 | Volume: 10 | Issue: 22 | Pages: No page available

10.1161/jaha.120.019697 | PMID 34658259 Get It

Background This study evaluated the role of supplementing Society of Thoracic Surgeons (STS) risk models for surgical aortic valve replacement with machine learning (ML). Methods and Results Adults undergoing isolated surgical aortic valve replacement in the STS National Database between 2007 and 2017 were included. ML models for operative mortality and major morbidity were previously developed using extreme gradient boosting. Concordance and discordance in predicted risk between ML and STS models were defined using equal‐size tertile‐based thresholds of risk. Calibration metrics and discriminatory capability were compared between concordant and discordant patients. A total of 243 142 patients were included. Nearly all calibration metrics were improved in cases of concordance. Similarly, concordance indices improved substantially in cases of concordance for all models with the exception of deep sternal wound infection. The greatest improvements in concordant versus discordant cases were in renal failure: ML model (concordance index, 0.660 [95% CI, 0.632–0.687] discordant versus 0.808 [95% CI, 0.794–0.822] concordant) and STS model (concordance index, 0.573 [95% CI, 0.549–0.576] discordant versus 0.797 [95% CI, 0.782–0.811] concordant) (each P <0.001). Excluding deep sternal wound infection, the concordance indices ranged from 0.549 to 0.660 for discordant cases and 0.674 to 0.808 for concordant cases. Conclusions Supplementing ML models with existing STS models for surgical aortic valve replacement may have an important role in risk prediction and should be explored further. In particular, for the roughly 25% to 50% of patients demonstrating discordance in estimated risk between ML and STS, there appears to be a substantial decline in predictive performance suggesting vulnerability of the existing models in these patient subsets.
Weighing the Risk and Benefits of Direct Oral Anticoagulants in Morbidly Obese Patients: New Data and Guidance
Houghton, Damon E. , Wysokiński, Waldemar E.

Mayo Clinic

The Hematologist | October 18, 2021 | Volume: 18 | Issue: 6 | Pages: No page available

10.1182/hem.v18.6.2021610 Get It

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension
Chen, Horng H. , Wan, Siu‐Hin , Cannone, Valentina , Sangaralingham, S. Jeson , Nuetel, Joel, Burnett, John C. , Iyer, Seethalakshmi R., Sangaralingham, S. Jeson , Iyer, Seethalakshmi

Mayo Clinic

Hypertension | October 18, 2021 | Volume: 78 | Issue: 6 | Pages: 1859-1867

10.1161/hypertensionaha.121.17159 | PMID 34657445 Get It

M-atrial natriuretic peptide (MANP) is a novel ANP (atrial natriuretic peptide) analog engineered to be an innovative particulate GC-A (guanylyl cyclase A) receptor activator. The rationale for its design was to develop a best-in-class GC-A activator with enhanced cGMP activating, natriuretic, aldosterone-suppressing, and blood pressure–lowering actions, compared with endogenous ANP, for the treatment of hypertension. Here, we report the first-in-human study on the safety, tolerability, neurohumoral, renal, and blood pressure–lowering properties of MANP in hypertension subjects. This was an open-label sequential single ascending dose design in which all subjects stopped all antihypertensive agents for 14 days before receiving a single subcutaneous injection of MANP. MANP was safe, well tolerated, activated cGMP, induced natriuresis, reduced aldosterone, and decreased blood pressure at or below the maximal tolerated dose. Thus, MANP has a favorable safety profile and produced expected pharmacological effects in human hypertension. Our results support further investigations of MANP as a potential future blood pressure–lowering, natriuretic and aldosterone-suppressing drug for hypertension especially resistant hypertension.
Genetic features and clinical outcomes of patients with isolated and comutated DDX41 -mutated myeloid neoplasms
Nanaa, Ahmad , Viswanatha, David S., Foran, James M. , Badar, Talha , Sproat, Lisa, He, Rong , Nguyen, Phuong L., Salama, Mohamad E., Greipp, Patricia T. , Gangat, Naseema , Tefferi, Ayalew , Litzow, Mark R. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Al‐Kali, Aref , Nanaa, Ahmad , Viswanatha, David, Badar, Talha , He, Rong , Greipp, Patricia, Litzow, Mark R. , Shah, Mithun V , Patnaik, Mrinal , Greipp, Patricia T , Alkhateeb, Hassan B. , Jevremović, Dragan , Shah, Meera

Mayo Clinic

Blood Advances | October 18, 2021 | Volume: 6 | Issue: 2 | Pages: 528-532

10.1182/bloodadvances.2021005738 | PMID 34644397 Get It

Abstract DDX41 mutations (germline and somatic) are associated with late onset myelodysplastic syndromes/acute myeloid leukemia (MDS/AML). Myeloid neoplasms (MN) with germline predisposition was identified as a distinct category in the 2016 WHO classification revision, including MN with germline DDX41 mutation. We retrospectively analyzed the molecular findings and clinical characteristics of thirty-three DDX41-mutated (mDDX41) patients at our institution. We identified 14 distinct pathogenic DDX41 variants in 32 patients and 8 DDX41 variants of unknown significance (VUS) in 9 patients. Five (16%) patients had a second DDX41 somatic mutation p.R525H and 13 (40%) had at least one additional oncogenic co-mutation in other genes. The median age at the time of diagnosis was 66 years, with male predominance (72%) and the majority of patients had normal cytogenetics (91%). Two-year overall survival (OS) was 86% and 6 (21%) MDS/AML patients with relatively preserved hematopoietic function were observed without further intervention. In comparison to AML patients with prognostically more favorable subtypes [t(8;21), n=27 and inv(16), n=40], mDDX41 patients in our cohort showed similarly favorable OS. Our study highlights that mDDX41-MN patients often have an indolent course and mDDX41-AML has comparable OS to favorable-risk AML.
A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration
Mirzaei, Navid Mohammad , Su, Sumeyye , Sofia, Dilruba , Hegarty, Maura, Abdel‐Rahman, Mohamed H. , Asadpoure, Alireza , Cebulla, Colleen M. , Chang, Young Hwan , Hao, Wenrui , Tatárová, Zuzana , Zervantonakis, Ioannis K. , Shahriyari, Leili , Mohammad Mirzaei, Navid , Jackson, Pamela R, Shahriyari, Leili , Jackson, Pamela , Lee, Adrian V. , Stover, Daniel G.

Mayo Clinic

Journal of Personalized Medicine | October 17, 2021 | Volume: 11 | Issue: 10 | Pages: 1031

10.3390/jpm11101031 | PMID 34683171 Get It

Breast cancer is the most prominent type of cancer among women. Understanding the microenvironment of breast cancer and the interactions between cells and cytokines will lead to better treatment approaches for patients. In this study, we developed a data-driven mathematical model to investigate the dynamics of key cells and cytokines involved in breast cancer development. We used gene expression profiles of tumors to estimate the relative abundance of each immune cell and group patients based on their immune patterns. Dynamical results show the complex interplay between cells and molecules, and sensitivity analysis emphasizes the direct effects of macrophages and adipocytes on cancer cell growth. In addition, we observed the dual effect of IFN-γ on cancer proliferation, either through direct inhibition of cancer cells or by increasing the cytotoxicity of CD8+ T-cells.
Impact of Aortic Valve Replacement for Severe Aortic Stenosis on Organic and Functional Mitral Regurgitation
Kato, Nahoko , Thaden, Jeremy J. , Miranda, William R. , Scott, Christopher G. , Greason, Kevin L. , Pellikka, Patricia A. , Sarano, Maurice E, Pellikka, Patricia A , Scott, Christopher , Enriquez-Sarano, Maurice , Enriquez‐Sarano, Maurice

Mayo Clinic

ESC Heart Failure | October 17, 2021 | Volume: 8 | Issue: 6 | Pages: 5482-5492

10.1002/ehf2.13649 | PMID 34652057 Get It

Abstract Aims Concurrent mitral regurgitation (MR) influences treatment considerations in patients with severe aortic stenosis (sAS). Limited information exists regarding haemodynamic effects of sAS on MR severity and outcome of these patients. We assessed the impact of aortic valve replacement (AVR) on MR according to mechanism in patients with sAS and MR. Methods and results In patients with sAS who received surgical or transcatheter AVR from 2008 to 2017, those with effective mitral regurgitant orifice area (ERO) ≥ 10 mm2 prior to AVR were evaluated. The change in MR after AVR was considered significant when there was at least one grade difference. We compared the all-cause mortality of patients with and without improvement in MR. Of 234 patients with sAS and MR (age 80 ± 9 years, 52% male, ERO 19 ± 7 mm2), organic and functional MR were present in 166 (71%) and 68 (29%), respectively. MR improved in 136 (58%); improvement occurred with similar frequency in organic versus functional MR (59% and 57%, P = 0.88). Associated determinants were absence of atrial fibrillation in organic MR [odds ratio (OR) 2.09, 95% confidence interval (CI) 1.00–4.37; P = 0.049] and indexed aortic valve area (iAVA) ≤ 0.40 cm2 in functional MR (OR 3.28, 95% CI 1.13–9.47; P = 0.028). In the overall cohort, mitral annulus diameter &lt; 3 cm (OR 1.74, 95% CI 1.02–2.97; P = 0.041) and QRS duration &lt; 115 ms (OR 1.73, 95% CI 1.00–2.98; P = 0.049) were independently associated with improvement in MR. During median follow-up of 3.5 years, lack of improvement in MR was not associated with higher mortality in the overall cohort of patients with ERO ≥ 20 mm2 [adjusted hazard ratio (HR) 1.71, 95% CI 0.90–3.27; P = 0.10, adjusted for age, New York Heart Association III or IV, diabetes, and creatinine ≥ 2.0 mg/dL]. Lack of improvement in organic MR was associated with higher mortality (adjusted HR 3.36, 95% CI 1.40–8.05; P &lt; 0.01). In patients with functional MR, change in MR was not associated with mortality (HR 1.24, 95% CI 0.44–3.47; P = 0.68). Conclusions In nearly 60% of patients with sAS and MR, MR improved after AVR, even in the majority of patients with organic MR. Absence of atrial fibrillation in organic MR, iAVA ≤ 0.40 cm2 in functional MR, and mitral annulus diameter &lt; 3 cm and QRS duration &lt; 115 ms in the overall population were associated with MR improvement. Post-operative improvement in organic MR was associated with better survival.
3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome
Greenmyer, Jacob R. , Thompson, Whitney S. , Hoppman, Nicole L., Khan, Shakila P. , Patnaik, Mrinal S., Schimmenti, Lisa A. , Kohorst, Mira A. , Khan, Shakila, Schimmenti, Lisa A , Thompson, Whitney S , Patnaik, Mrinal S.

Mayo Clinic

British Journal of Haematology | October 17, 2021 | Volume: 196 | Issue: 4 | Pages: 1120-1123

10.1111/bjh.17902 | PMID 34651298 Get It

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Rollot, Fabien , Mondot, Lydiane, Louapre, Céline , Page, Emmanuelle Le , Durand‐Dubief, Françoise , Labauge, Pierre, Bensa, Caroline , Thouvenot, Éric , Ciron, Jonathan , Bourre, Bertrand , Cabre, Philippe, Casez, Olivier , Ruet, Aurélie , Mathey, Guillaume , Berger, Éric , Moreau, Thibault, Khedr, A. Al, Derache, Nathalie, Guennoc, Anne‐Marie, Créange, Alain , Neau, Jean‐Philippe, Tourbah, Ayman , Camdessanché, Jean‐Philippe , Maarouf, Adil , Callier, Céline, Kantarci, Orhun H. , Sıva, Aksel , Azevedo, Christina , Makhani, Naila , Pelletier, Daniel , Investigators, RISC, SFSEP, and OFSEP, Pelletier, Daniel, Azevedo, Christina, Radji, Fataï, Morel, Nathalie, Grosset-Jeannin, Deborah, Ungureanu, Aurelian , Boyer, L, Suchet, Laurent , Elias, Zyad, Brochet, Bruno, Defer, Gilles , Branger, Pierre , Clavelou, Pierre, Taithe, Frédéric, Alkhedr, Adullatif, Fromont, Agnès, Hautecoeur, Patrick, Androdias, G. , Ionescu, Iuliana, Pelletier, Jean , Audoin, Bertrand , Labauge, Pierre, Debouverie, Marc, Laplaud, David, Wiertlevski, Sandrine, Bresch, Saskia , Castelnovo, Giovanni, Papeix, Caroline , Lubetzki, Catherine , Stankoff, Bruno, Fontaine, Bertrand , Giannesini, C. , Heinzleff, Olivier, Bourre, Bertrand, Gout, Olivier , Guegen, Antoine, Leray, Emmanuelle , Guennoc, Anne Marie , Broucker, T. de , Sehaki, Sabrina, Devys-Meyer, Nathalie, Bereau, Mathieu, Cappe, Chrystelle, Kounkou, Katy-Kim, Dumont, Émilie , Lescieux, Edwige, Protin, Alexia, Kane, Maty Diop, Boucher, Julie, Petit, Julie, Kasonde, Irène Tabellah, Vilmarrest, Aymeric de, Nicol, Marie , Malbezin, Muriel, Olaiz, Javier, Rigaud-Bully, Claire, Vukusic, Irena, Debard, Nadine, Cotton, François, Abdelalli, Amalle, Lelio, Bernadette Di, Pinna, Frédéric , Guillemin, Francis, Ziegler, Amandine, Zehrouni, Karima, Hodel, Jérôme , Wahab, Abir , Zedet, Mickaël, Fagniez, Ombeline, Laage, Clémence, Pottier, Corinne , Slesari, Iuliana, Sampaio, Mathilde, Rabois, Emilie, Castex, Cédric , Hébant, Benjamin , Guillaume, Maxime , Vimont, Christine, Muraz, Romain, Port, Damien Le, Henry, Carole , Berthe, Carole, Freitas, Noellie, Visneux, Vincent, Forestier, M., Beltran, S. , Meunier, Géraldine, Servan, Jérôme, Pico, Fernando, Chatagner, Virginie, Siva, Aksel , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Lebrun‐Frénay, Christine , Mondot, Lydiane , Zéphir, Hélène , Laplaud, David , Seze, Jerome De , Bourre, Bertrand , Casez, Olivier , Clavelou, Pierre , Vermersch, Patrick , Cohen, Mikaël , Okuda, Darin T. , Vukusic, Sandra , Investigators, RISC, SFSEP, and OFSEP, Azevedo, Christina, Morel, Nathalie, Boyer, Latine, Ouallet, Jean‐Christophe , Clavelou, Pierre, Outteryck, Olivier , Hautecoeur, Patrick, Ayrignac, Xavier , Carra‐Dallière, Clarisse , Labauge, Pierre, Laplaud, David, Maillart, Elisabeth , Bourre, Bertrand, Michel, Laure , Magy, Laurent , Collongues, Nicolas , Biotti, Damien , Béreau, Matthieu , Casey, Romain , Muraz, Romain, Forestier, Melanie

Mayo Clinic

JAMA Network Open | October 17, 2021 | Volume: 4 | Issue: 10 | Pages: e2128271

10.1001/jamanetworkopen.2021.28271 | PMID 34633424 Get It

Primary tumor resection in patients with stage IV breast cancer: 10‐year experience
Jakub, James W. , Yonkus, Jennifer A. , Jakub, James W , Asaad, Malke , Hoskin, Tanya L. , Hieken, Tina J. , Boughey, Judy C. , Degnim, Amy C.

Mayo Clinic

The Breast Journal | October 17, 2021 | Volume: 27 | Issue: 12 | Pages: 863-871

10.1111/tbj.14294 | PMID 34651376 Get It